iSpecimen

iSpecimen, Inc. operates as healthcare organization that engages in procurement of human biospecimens. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in July 2009 and is headquartered in Lexington, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

iSpecimen reports improved Q1 performance, eyes growth opportunities ahead

iSpecimen's Q1 2024 earnings call highlighted improved financial performance through cost management and sales growth initiatives.
While facing challenges of lower specimen counts, the company showcased strengths in pricing power, supply efficiency, and cash position.
Opportunities lie in leveraging successful programs, exploring new markets, investing in technology, and strategic partnerships for future growth.
Overall, iSpecimen's positive outlook on operational advancements signals a commitment to sustainable growth and innovation in the healthcare sector.

iSpecimen beats revenue targets, strengthens operations for future growth

iSpecimen delivered strong Q2 2024 results, surpassing revenue targets and improving operational efficiency. The company's strategic initiatives to reduce costs, optimize workforce, and enhance supplier relationships are driving growth. While challenges like funding needs persist, iSpecimen is well-positioned for future opportunities in the healthcare specimen sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

iSpecimen, Inc. is a healthcare organization that engages in procurement of human biospecimen. It collects biofluids, human tissue, hematopoietic stem, and immune cells. The company was founded by Christopher Ianelli in 2009 and is headquartered in Woburn, MA.

New Feature Provides Suppliers with Research Transparency to Optimize Fulfillment Process New Feature Provides Suppliers with Research Transparency to Optimize Fulfillment Process

iSpecimen Launches New Open Feasibilities Dashboard on the iSpecimen Marketplace Platform to Enhance Biospecimen Fulfillment for Global Partner Network

LEXINGTON, Mass., Oct. 25, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the third quarter ended September 30, 2022, before the markets open on Tuesday, November 8, 2022.

iSpecimen to Report Third Quarter 2022 Results on November 8, 2022

Lexington, Massachusetts--(Newsfile Corp. - October 18, 2022) - iSpecimen Inc. (NASDAQ: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that Tracy Curley, Interim CEO and CFO of iSpecimen, will present at the ThinkEquity Conference to be held at the Mandarin Oriental Hotel in New York City on October 26, 2022 at 4:30 p.m. ET.

iSpecimen to Participate in the ThinkEquity Conference on October 26, 2022

New Program Designed to Support Provider Partners with Onsite Coordinator New Program Designed to Support Provider Partners with Onsite Coordinator

iSpecimen Launches Marketplace Onsite Program to Optimize Biospecimen Procurement Process for Sample Providers

Current President and CEO, Christopher Ianelli, to Leave Company Current President and CEO, Christopher Ianelli, to Leave Company

iSpecimen Names Chief Financial Officer, Tracy Curley, Interim CEO

LEXINGTON, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc.  (Nasdaq: ISPC) ("iSpecimen" or the "Company"), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that Christopher Ianelli, MD, PhD, CEO and President of iSpecimen, will participate in the H.C. Wainwright 24th Annual Global Investment Conference to be held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022.

iSpecimen to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022

iSpecimen Inc. (NASDAQ:ISPC ) Q2 2022 Earnings Conference Call August 4, 2022 8:30 AM ET Company Participants Allison Soss - Senior Vice President of Investor Relations Christopher Ianelli - President & Chief Executive Officer Jill Mullan - Chief Operating Officer Tracy Curley - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Capital Group Constantine Davides - EF Hutton James Lieberman - Revere Securities Operator Good day, everyone and welcome to iSpecimen Second Quarter 2022 Conference Call. [Operator Instructions] A replay of today's call will be available on the Investor Relations section of iSpecimen's website and will remain posted there for the next 30 days.

iSpecimen Inc. (ISPC) CEO Christopher Ianelli on Q2 2022 Results - Earnings Call Transcript

Enhanced iSpecimen Marketplace® Platform with Data Integration Capabilities to Simplify the Ingestion and Maintenance of Biospecimen Inventories for Providers Enhanced iSpecimen Marketplace® Platform with Data Integration Capabilities to Simplify the Ingestion and Maintenance of Biospecimen Inventories for Providers

iSpecimen Reports Second Quarter 2022 Financial and Operating Results

LEXINGTON, Mass., July 21, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that it will report its financial results for the second quarter ended June 30, 2022, before the markets open on Thursday, August 4, 2022.

iSpecimen to Report Second Quarter 2022 Results on August 4, 2022

iSpecimen Inc (NASDAQ: ISPC) has added new global biospecimen suppliers to its proprietary Marketplace platform for advancing oncology and cardiovascular disease research. The new suppliers include a cancer-focused biobank in the U.S., which contains a differentiated range of pre-.

Why iSpecimen Shares Are Gaining Today?

New Suppliers Will Increase Access to Unique Banked Biospecimens for Advancing Oncology and Cardiovascular Disease Research New Suppliers Will Increase Access to Unique Banked Biospecimens for Advancing Oncology and Cardiovascular Disease Research

iSpecimen Adds New Global Biospecimen Suppliers to Proprietary Marketplace Platform for Researchers to Leverage

Industry Veteran Brings Nearly Two Decades of Experience in Healthcare Product Management to the Company Industry Veteran Brings Nearly Two Decades of Experience in Healthcare Product Management to the Company

iSpecimen Appoints Evan Cox as Vice President of Product Management

Company Gave Three Presentations, Including Oral Discussion on How New Technology Can Support the “Just-in-Time” Approach to Biobanking

iSpecimen Presents New Research to Optimize Biobanking at International Society for Biological and Environmental Repositories 2022 Annual Meeting

LEXINGTON, Mass., May 16, 2022 (GLOBE NEWSWIRE) --   iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, today announced that Christopher Ianelli, MD, PhD, CEO and President of iSpecimen, will participate virtually in the H.C. Wainwright Global Investment Conference to be held on May 23-26, 2022.

iSpecimen to Participate in the H.C. Wainwright Global Investment Conference on May 23-26, 2022

iSpecimen Inc. (NASDAQ:ISPC ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Allison Soss - Investor Relations Christopher Ianelli - Chief Executive Officer and President Tracy Curley - Chief Financial Officer Jill Mullan - Chief Operating Officer Conference Call Participants Matthew Hewitt - Craig-Hallum Capital Group Constantine Davides - EF Hutton Operator Good day, everyone, and welcome to iSpecimen's First Quarter 2022 Conference Call. [Operator Instructions] This conference is being recorded.

iSpecimen Inc. (ISPC) CEO Christopher Ianelli on Q1 2022 Results - Earnings Call Transcript

- Recently Launched Enhanced iSpecimen Marketplace Platform to Help Scientists More Efficiently Search for Biospecimens - - Recently Launched Enhanced iSpecimen Marketplace Platform to Help Scientists More Efficiently Search for Biospecimens -

iSpecimen Reports First Quarter 2022 Financial and Operating Results

LEXINGTON, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), a global, online marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare providers who have them, today announced that it will report its financial results for the first quarter ended March 31, 2022, before the markets open on Tuesday, May 10, 2022.

iSpecimen to Report First Quarter 2022 Results on May 10, 2022

Updated Interface Provides Improved Search and Data Integration Capabilities

iSpecimen Unveils Enhanced iSpecimen Marketplace Platform to Help Scientists More Efficiently Find Desired Biospecimens for Research

The iSpecimen Marketplace Platform Now Provides Custom Sequencing for Cancer and COVID-19 Biofluid and Tissue Samples The iSpecimen Marketplace Platform Now Provides Custom Sequencing for Cancer and COVID-19 Biofluid and Tissue Samples

iSpecimen Adds Acutis Diagnostics to Marketplace Platform to Support Oncology and Infectious Disease Research

LEXINGTON, Mass., March 15, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), a global, proprietary online marketplace connecting scientists with healthcare providers to search for biospecimens needed for medical research, today announced that Christopher Ianelli, MD, PhD, CEO and President of iSpecimen, will participate in Maxim Group's 2022 Virtual Growth Conference to be held virtually on March 28-30, 2022.

iSpecimen to Participate in Maxim's 2022 Virtual Growth Conference on March 28-30, 2022

- Proprietary Marketplace Provides Easy Access to Urgently-Needed Tissues, Biofluids and Cells for Lifesaving Medical Research -

iSpecimen's Global Biospecimen Marketplace Surpasses 200 Suppliers

iSpecimen Inc. (ISPC) CEO Christopher Ianelli on Q4 2021 Results - Earnings Call Transcript

Record FY 2021 Revenue of $11.1 Million, Surpassing FY 2020 Revenue of $8.2 Million by 36% Record FY 2021 Revenue of $11.1 Million, Surpassing FY 2020 Revenue of $8.2 Million by 36%

iSpecimen Reports Full Year 2021 Financial Results

LEXINGTON, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ: ISPC) (“iSpecimen” or the “Company”), an online marketplace for human biospecimens, today announced that Christopher Ianelli, MD, PhD, CEO and President, will participate in the Aegis Capital Corp. Virtual Conference to be held virtually on February 23-25, 2022.

iSpecimen to Participate in the Aegis Virtual Conference on February 24, 2022

LEXINGTON, Mass., Feb. 03, 2022 (GLOBE NEWSWIRE) -- iSpecimen Inc. (NASDAQ: ISPC) (“iSpecimen” or the “Company”), an online marketplace for human biospecimens, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2021, before the markets open on Thursday, February 17, 2022.

News for iSpecimen Stock (ISPC)